Vernus AI Makes Its US BIO Debut — ReAIX Digital Twin Platform Draws International Interest
At the BIO International Convention, Vernus AI presented ReAIX to pharma and biotech companies from three regions. Several conversations have moved to in-depth evaluation.
On June 24, 2026, Vernus AI made its first appearance at the BIO International Convention, the world's largest biotechnology event.
We presented ReAIX, our AI platform for pharmaceutical manufacturing, in business meetings with multinational pharmaceutical companies and biotech partners from North America, Europe and Asia-Pacific.
A digital twin platform for manufacturing
ReAIX brings together AI agents, quantum computing and physics simulation to build high-fidelity digital twins of manufacturing processes. Several partnership discussions started at the event have since moved to in-depth evaluation.
Sources and coverage
About Vernus AI
Vernus AI (睿泉生技) builds ReAIX, a family of platforms that combine AI, physics-based simulation and annealing-based optimization to help pharmaceutical teams find better process conditions with fewer experiments.